Dr. Pollack on the Future Treatment Landscape for Sarcoma

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Regarding radiomics, Pollack envisions this novel treatment approach will have a role in the future.

Additionally, Pollack says that he is very excited for the field of sarcoma to move toward immunotherapy in the next 5 to 10 years. The data from SARC028, which investigated treatment with the PD-1 inhibitor pembrolizumab (Keytruda) holds promise for patients with pleomorphic undifferentiated sarcoma. Another ongoing clinical trial is exploring the combination trial of doxorubicin plus pembrolizumab, which also is exciting, Pollack adds.